|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
RU2658490C2
(ru)
|
2012-03-27 |
2018-06-21 |
Кьюрвак Аг |
Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
|
|
CN105073135A
(zh)
|
2013-02-22 |
2015-11-18 |
库瑞瓦格有限责任公司 |
疫苗接种和抑制pd-1途径的组合
|
|
SG11201510746WA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Respiratory syncytial virus (rsv) vaccine
|
|
AU2014310935B2
(en)
|
2013-08-21 |
2019-11-21 |
CureVac SE |
Combination vaccine
|
|
SG11201510747RA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
|
BR112016001192A2
(pt)
|
2013-08-21 |
2017-08-29 |
Curevac Ag |
Vacina contra a raiva
|
|
ES2806575T3
(es)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
ARN modificado con propiedades inmunoestimuladoras disminuidas
|
|
WO2015101414A2
(en)
|
2013-12-30 |
2015-07-09 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
|
WO2015101416A1
(en)
|
2013-12-30 |
2015-07-09 |
Curevac Gmbh |
Methods for rna analysis
|
|
JP6584414B2
(ja)
|
2013-12-30 |
2019-10-02 |
キュアバック アーゲー |
人工核酸分子
|
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
US10307472B2
(en)
|
2014-03-12 |
2019-06-04 |
Curevac Ag |
Combination of vaccination and OX40 agonists
|
|
WO2015149944A2
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Gmbh |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
SG11201608605QA
(en)
|
2014-06-10 |
2016-12-29 |
Curevac Ag |
Methods and means for enhancing rna production
|
|
IL289934B2
(en)
|
2014-06-25 |
2023-04-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP4241784A3
(en)
*
|
2014-12-12 |
2023-11-15 |
CureVac SE |
Artificial nucleic acid molecules for improved protein expression
|
|
KR102580696B1
(ko)
*
|
2014-12-30 |
2023-09-19 |
큐어백 에스이 |
신규 인공 핵산 분자
|
|
EP4353257A3
(en)
|
2015-04-13 |
2024-08-07 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
CN107567497A
(zh)
|
2015-04-17 |
2018-01-09 |
库瑞瓦格股份公司 |
Rna的冻干
|
|
WO2016170176A1
(en)
|
2015-04-22 |
2016-10-27 |
Curevac Ag |
Rna containing composition for treatment of tumor diseases
|
|
EP3289083A4
(en)
|
2015-04-27 |
2018-12-19 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
ES2897823T3
(es)
|
2015-04-30 |
2022-03-02 |
Curevac Ag |
Poli(N)polimerasa inmovilizada
|
|
EP3294885B1
(en)
|
2015-05-08 |
2020-07-01 |
CureVac Real Estate GmbH |
Method for producing rna
|
|
AU2016264027A1
(en)
|
2015-05-15 |
2017-08-31 |
Curevac Ag |
Prime-boost regimens involving administration of at least one mRNA construct
|
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
EP3297682B1
(en)
|
2015-05-20 |
2021-07-14 |
CureVac AG |
Dry powder composition comprising long-chain rna
|
|
WO2016193206A1
(en)
|
2015-05-29 |
2016-12-08 |
Curevac Ag |
A method for producing and purifying rna, comprising at least one step of tangential flow filtration
|
|
US11608513B2
(en)
|
2015-05-29 |
2023-03-21 |
CureVac SE |
Method for adding cap structures to RNA using immobilized enzymes
|
|
CN114085198A
(zh)
|
2015-06-29 |
2022-02-25 |
爱康泰生治疗公司 |
用于递送核酸的脂质和脂质纳米颗粒制剂
|
|
US10501768B2
(en)
|
2015-07-13 |
2019-12-10 |
Curevac Ag |
Method of producing RNA from circular DNA and corresponding template DNA
|
|
WO2017036580A1
(en)
|
2015-08-28 |
2017-03-09 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
EP3350157B1
(en)
|
2015-09-17 |
2022-01-05 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2017059902A1
(en)
*
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
WO2017064146A1
(en)
|
2015-10-12 |
2017-04-20 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
|
JP2018530587A
(ja)
|
2015-10-16 |
2018-10-18 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
mRNAキャップ類似体およびmRNAキャッピングの方法
|
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
|
ES2914225T3
(es)
|
2015-10-16 |
2022-06-08 |
Modernatx Inc |
Análogos de cap de ARNm con enlace de fosfato modificado
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
MA47016A
(fr)
|
2015-10-22 |
2018-08-29 |
Modernatx Inc |
Vaccins contre les virus respiratoires
|
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
EP4582098A3
(en)
|
2015-11-09 |
2025-12-24 |
CureVac SE |
Optimized nucleic acid molecules
|
|
EP3373965A1
(en)
|
2015-11-09 |
2018-09-19 |
CureVac AG |
Rotavirus vaccines
|
|
SI3394030T1
(sl)
|
2015-12-22 |
2022-04-29 |
Modernatx, Inc. |
Sestave za doziranje sredstev v celice
|
|
CN108778308A
(zh)
|
2015-12-22 |
2018-11-09 |
库瑞瓦格股份公司 |
生产rna分子组合物的方法
|
|
US11248223B2
(en)
|
2015-12-23 |
2022-02-15 |
Curevac Ag |
Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
SG11201806340YA
(en)
|
2016-02-17 |
2018-09-27 |
Curevac Ag |
Zika virus vaccine
|
|
US11920174B2
(en)
|
2016-03-03 |
2024-03-05 |
CureVac SE |
RNA analysis by total hydrolysis and quantification of released nucleosides
|
|
EP3442590A2
(en)
|
2016-04-13 |
2019-02-20 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
|
EP4487869A3
(en)
*
|
2016-04-22 |
2025-07-30 |
CureVac SE |
Rna encoding a tumor antigen
|
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
|
US11141474B2
(en)
|
2016-05-04 |
2021-10-12 |
Curevac Ag |
Artificial nucleic acid molecules encoding a norovirus antigen and uses thereof
|
|
US11078247B2
(en)
|
2016-05-04 |
2021-08-03 |
Curevac Ag |
RNA encoding a therapeutic protein
|
|
EP4691484A2
(en)
|
2016-05-04 |
2026-02-11 |
CureVac SE |
Influenza mrna vaccines
|
|
EP3458083B1
(en)
|
2016-05-18 |
2022-11-02 |
ModernaTX, Inc. |
Polynucleotides encoding interleukin-12 (il12) and uses thereof
|
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
CA3023174A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
US20200069599A1
(en)
|
2016-06-14 |
2020-03-05 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
WO2018096179A1
(en)
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
|
BR112019010486A2
(pt)
*
|
2016-11-28 |
2019-09-10 |
Napajen Pharma Inc |
sirna quimicamente modificado
|
|
WO2018102397A1
(en)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
MA50335A
(fr)
|
2016-12-08 |
2020-08-19 |
Modernatx Inc |
Vaccins à acide nucléique contre des virus respiratoires
|
|
JP2020501545A
(ja)
*
|
2016-12-08 |
2020-01-23 |
キュアバック アーゲー |
肝疾患の処置または予防のためのrna
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
|
US11524066B2
(en)
|
2016-12-23 |
2022-12-13 |
CureVac SE |
Henipavirus vaccine
|
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
|
US11241490B2
(en)
|
2017-01-11 |
2022-02-08 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified RNA for inducing an immune response against zika virus
|
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
|
FI3596041T3
(fi)
|
2017-03-15 |
2023-01-31 |
|
Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
|
|
EP3595676A4
(en)
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
KR102842382B1
(ko)
|
2017-03-24 |
2025-08-04 |
큐어백 에스이 |
Crispr-연관 단백질을 암호화하는 핵산 및 이의 용도
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
EP3618859A4
(en)
|
2017-04-27 |
2021-05-05 |
Vanderbilt University |
HEPATITIS C VIRUS SEQUENCES AND METHODS OF USING THEREFORE
|
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP3625363A1
(en)
|
2017-05-17 |
2020-03-25 |
CureVac Real Estate GmbH |
Method for determining at least one quality parameter of an rna sample
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
WO2018231990A2
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
BR112019028280A2
(pt)
|
2017-07-04 |
2020-07-14 |
Curevac Ag |
moléculas de ácido nucleico
|
|
WO2019036008A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
JP7461872B2
(ja)
|
2017-08-17 |
2024-04-04 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
WO2019036638A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR PREPARING MODIFIED RNA
|
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
|
AU2018326799A1
(en)
|
2017-08-31 |
2020-02-27 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
US11692002B2
(en)
|
2017-11-08 |
2023-07-04 |
CureVac SE |
RNA sequence adaptation
|
|
WO2019115635A1
(en)
|
2017-12-13 |
2019-06-20 |
Curevac Ag |
Flavivirus vaccine
|
|
SG11202005760PA
(en)
|
2017-12-21 |
2020-07-29 |
Curevac Ag |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
WO2019193183A2
(en)
*
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
SG11202008225PA
(en)
|
2018-04-17 |
2020-11-27 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
|
US12371646B2
(en)
|
2018-06-28 |
2025-07-29 |
CureVac Manufacturing GmbH |
Bioreactor for RNA in vitro transcription
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
EP4613367A1
(en)
|
2018-09-21 |
2025-09-10 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
BR112021006074A2
(pt)
*
|
2018-11-05 |
2021-07-20 |
The University Of North Carolina At Chapel Hill |
genes e cassetes de expressão fig4 otimizados e seu uso
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
US12492425B2
(en)
|
2018-12-21 |
2025-12-09 |
CureVac SE |
Methods for RNA analysis
|
|
JP7635131B2
(ja)
|
2019-01-31 |
2025-02-25 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の調製方法
|
|
SG11202108098QA
(en)
|
2019-01-31 |
2021-08-30 |
Modernatx Inc |
Vortex mixers and associated methods, systems, and apparatuses thereof
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
US20230000908A1
(en)
*
|
2019-09-11 |
2023-01-05 |
Ohio State Innovation Foundation |
Engineered cells and uses thereof
|
|
AU2021213108A1
(en)
|
2020-01-28 |
2022-08-18 |
Modernatx, Inc. |
Coronavirus RNA vaccines
|
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
KR20220140528A
(ko)
|
2020-02-07 |
2022-10-18 |
모더나티엑스, 인크. |
Sars-cov-2 mrna 도메인 백신
|
|
CN113874507A
(zh)
|
2020-04-09 |
2021-12-31 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
KR102924173B1
(ko)
|
2020-04-09 |
2026-02-06 |
쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 |
지질 나노입자 조성물
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
CA3182994A1
(en)
|
2020-06-30 |
2022-01-06 |
Bo YING |
Lipid compounds and lipid nanoparticle compositions
|
|
DK4182297T3
(da)
|
2020-07-16 |
2025-12-01 |
Acuitas Therapeutics Inc |
Kationiske lipider til brug i lipid-nanopartikler
|
|
AU2021328980A1
(en)
|
2020-08-20 |
2023-03-09 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
WO2022047325A1
(en)
*
|
2020-08-31 |
2022-03-03 |
The Trustees Of Columbia University In The City Of New York |
Targeting of tgm4 to treat prostate cancer
|
|
US20230355743A1
(en)
|
2020-09-25 |
2023-11-09 |
Modernatx, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
|
TW202233232A
(zh)
|
2020-11-06 |
2022-09-01 |
法商賽諾菲公司 |
遞送mRNA疫苗的脂質奈米顆粒
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
US12329811B2
(en)
|
2021-01-11 |
2025-06-17 |
Modernatx, Inc. |
Seasonal RNA influenza virus vaccines
|
|
WO2022152141A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Polymer conjugated lipid compounds and lipid nanoparticle compositions
|
|
WO2022152109A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
AU2022208057A1
(en)
|
2021-01-15 |
2023-08-03 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
CA3208303A1
(en)
|
2021-01-15 |
2022-07-21 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
CN114908089B
(zh)
*
|
2021-02-08 |
2024-03-15 |
上海细胞治疗集团有限公司 |
3’utr的构建方法和应用
|
|
WO2022197624A1
(en)
|
2021-03-15 |
2022-09-22 |
Modernatx, Inc. |
Therapeutic use of sars-cov-2 mrna domain vaccines
|
|
AU2022258335A1
(en)
|
2021-04-13 |
2023-11-23 |
Modernatx, Inc. |
Respiratory virus combination vaccines
|
|
WO2022221440A1
(en)
|
2021-04-14 |
2022-10-20 |
Modernatx, Inc. |
Influenza-coronavirus combination vaccines
|
|
WO2022245888A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Seasonal flu rna vaccines and methods of use
|
|
EP4204390A1
(en)
|
2021-05-24 |
2023-07-05 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
KR20240022610A
(ko)
|
2021-06-18 |
2024-02-20 |
사노피 |
다가 인플루엔자 백신
|
|
AU2021461416A1
(en)
|
2021-08-24 |
2024-02-22 |
BioNTech SE |
In vitro transcription technologies
|
|
CN118317944A
(zh)
|
2021-09-14 |
2024-07-09 |
雷纳嘉德医疗管理公司 |
非环状脂质及其使用方法
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
JP2024536406A
(ja)
|
2021-10-08 |
2024-10-04 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
JP2024539512A
(ja)
|
2021-10-22 |
2024-10-28 |
セイル バイオメディシンズ インコーポレイテッド |
Mrnaワクチン組成物
|
|
KR20240107146A
(ko)
|
2021-11-05 |
2024-07-08 |
사노피 |
호흡기 세포융합 바이러스 rna 백신
|
|
WO2023092069A1
(en)
|
2021-11-18 |
2023-05-25 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines and methods of use
|
|
CN118488834A
(zh)
|
2021-11-23 |
2024-08-13 |
赛欧生物医药股份有限公司 |
细菌源性脂质组合物和其用途
|
|
KR20240118798A
(ko)
|
2021-11-30 |
2024-08-05 |
사노피 파스퇴르 인크 |
인간 메타뉴모바이러스 백신
|
|
US20250360194A1
(en)
|
2021-12-08 |
2025-11-27 |
Modernatx, Inc. |
Herpes simplex virus mrna vaccines
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
CA3242439A1
(en)
|
2021-12-17 |
2023-06-22 |
Sanofi |
Lyme disease rna vaccine
|
|
EP4452239A1
(en)
|
2021-12-20 |
2024-10-30 |
Sail Biomedicines, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
|
JP2025502599A
(ja)
|
2021-12-23 |
2025-01-28 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
WO2023196914A1
(en)
|
2022-04-08 |
2023-10-12 |
Modernatx, Inc. |
Influenza nucleic acid compositions and uses thereof
|
|
WO2023230481A1
(en)
|
2022-05-24 |
2023-11-30 |
Modernatx, Inc. |
Orthopoxvirus vaccines
|
|
WO2024015890A1
(en)
|
2022-07-13 |
2024-01-18 |
Modernatx, Inc. |
Norovirus mrna vaccines
|
|
CN119654141A
(zh)
|
2022-08-18 |
2025-03-18 |
苏州艾博生物科技有限公司 |
脂质纳米颗粒的组合物
|
|
CA3265295A1
(en)
|
2022-08-22 |
2024-02-29 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
CORONAVIRUS VACCINES
|
|
WO2024050483A1
(en)
|
2022-08-31 |
2024-03-07 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines and uses thereof
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
US12186389B2
(en)
|
2022-10-28 |
2025-01-07 |
Glaxosmithkline Biologicals Sa |
Nucleic acid base vaccine against emerging SARS-CoV-2 variants
|
|
WO2024094881A1
(en)
|
2022-11-04 |
2024-05-10 |
Sanofi |
Respiratory syncytial virus rna vaccination
|
|
WO2024094876A1
(en)
|
2022-11-04 |
2024-05-10 |
Sanofi |
Methods for messenger rna tailing
|
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
JP2025541298A
(ja)
|
2022-12-15 |
2025-12-18 |
サノフィ パスツール インコーポレイテッド |
mRNA組換えキャッピング酵素
|
|
AU2023394992A1
(en)
|
2022-12-15 |
2025-07-31 |
Sanofi Pasteur Inc. |
Mrna encoding influenza virus-like particle
|
|
WO2024133884A2
(en)
|
2022-12-23 |
2024-06-27 |
Sanofi |
Optimized tailing of messenger rna
|
|
WO2024159172A1
(en)
|
2023-01-27 |
2024-08-02 |
Senda Biosciences, Inc. |
A modified lipid composition and uses thereof
|
|
WO2024163465A1
(en)
|
2023-01-30 |
2024-08-08 |
Modernatx, Inc. |
Epstein-barr virus mrna vaccines
|
|
WO2024180262A1
(en)
|
2023-03-02 |
2024-09-06 |
Sanofi |
Compositions for use in treatment of chlamydia
|
|
WO2024184489A1
(en)
|
2023-03-07 |
2024-09-12 |
Sanofi |
Manufacture of messenger rna with kp34 polymerase
|
|
AU2024234874A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
EP4680287A1
(en)
|
2023-03-15 |
2026-01-21 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
EP4694918A1
(en)
|
2023-04-10 |
2026-02-18 |
ModernaTX, Inc. |
Lyme disease vaccines
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
IL324411A
(en)
|
2023-05-05 |
2026-01-01 |
Sanofi Pasteur Inc |
Preparations for use in the treatment of acne
|
|
WO2024231565A1
(en)
|
2023-05-10 |
2024-11-14 |
Sanofi |
Combination respiratory mrna vaccines
|
|
WO2024254552A1
(en)
|
2023-06-08 |
2024-12-12 |
Modernatx, Inc. |
Stabilized flavivirus vaccines
|
|
WO2024263826A1
(en)
|
2023-06-22 |
2024-12-26 |
Modernatx, Inc. |
Sars-cov-2 t cell vaccines
|
|
CN121712487A
(zh)
|
2023-06-28 |
2026-03-20 |
赛诺菲巴斯德有限公司 |
脂质纳米颗粒配制品中的固醇类似物
|
|
WO2025019352A2
(en)
|
2023-07-14 |
2025-01-23 |
Modernatx, Inc. |
Mers-cov mrna vaccines
|
|
WO2025017151A1
(en)
|
2023-07-18 |
2025-01-23 |
Sanofi |
Stable poly(a)-encoding messenger rna templates
|
|
WO2025017202A2
(en)
|
2023-07-19 |
2025-01-23 |
Sanofi |
Porphyromonas gingivalis antigenic constructs
|
|
WO2025029700A1
(en)
|
2023-07-28 |
2025-02-06 |
Modernatx, Inc. |
Vlp enteroviral vaccines
|
|
WO2025034612A1
(en)
|
2023-08-04 |
2025-02-13 |
Modernatx, Inc. |
Varicella-zoster virus mrna vaccine
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
TW202527960A
(zh)
|
2023-09-06 |
2025-07-16 |
美商賽諾菲巴斯德公司 |
經修飾b型流感血球凝集素多肽及核酸及其用途
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025134071A1
(en)
|
2023-12-22 |
2025-06-26 |
Sanofi |
Malic and glutaric acid based ionizable lipids
|
|
WO2025141521A1
(en)
|
2023-12-29 |
2025-07-03 |
Sanofi |
Lipids having dendritic moieties
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025160191A2
(en)
*
|
2024-01-22 |
2025-07-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Composition and method for autonomous rna switches for translational control
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025210592A1
(en)
|
2024-04-05 |
2025-10-09 |
Sanofi Pasteur Inc. |
Muscle cell lnp-mrna quality control assays
|
|
WO2025226656A1
(en)
|
2024-04-23 |
2025-10-30 |
Modernatx, Inc. |
Hepatitis b virus mrna vaccines
|
|
WO2026008743A1
(en)
|
2024-07-02 |
2026-01-08 |
Sanofi Pasteur Inc. |
Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
|
|
WO2026027730A1
(en)
|
2024-07-31 |
2026-02-05 |
Sanofi |
Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
WO2026053147A1
(en)
|
2024-09-05 |
2026-03-12 |
Sanofi Pasteur Inc. |
Helper lipids and lnp compositions comprising same
|
|
WO2026052773A1
(en)
|
2024-09-06 |
2026-03-12 |
Sanofi |
Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof
|